$TTE

TotalEnergies launches the Ima Gas Development to Supply Nigeria LNG liquefaction plant

TotalEnergies and AMNI approved the Ima gas field development in Nigeria, with production starting in 2028. The field will supply gas for the Nigeria LNG Train 7 expansion, increasing liquefaction capacity to 30 Mtpa. The project is low-cost, low-emissions, and has strong Nigerian involvement.

Original reporting
Published Sep 25, 2026, 5:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 7:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TotalEnergies launches the Ima Gas Development to Supply Nigeria LNG liquefaction plant — source image
Decision brief

The 30-second read

$TTEBullishLow
01

Why it matters

The FID signals commitment to low‑emission gas projects and aligns with Nigeria's LNG expansion plans.

02

Market read

New upstream project adds to TotalEnergies' gas portfolio; modest but positive for energy sector sentiment.

03

What to watch

Potential regulatory or execution risks in Nigeria could delay the 2028 start‑up.

Relevance 6/10Novelty 7/10Timing: today

Background

TotalEnergies holds a 40% stake and is the operator of the Ima gas development, partnering with AMNI (60%).

Company-level read

Ticker impact

$TTEBullishMedium confidence
Context

TotalEnergies announced the Final Investment Decision for the Ima gas field, a new upstream project in Nigeria.

Expected impact

Modest upside pressure on TTE as the project expands gas reserves.

Evidence & confidence

The FID is a fresh, material development but the scale (350 MMcf/d) is modest relative to TotalEnergies' portfolio.

Market effects

Strengthens the global gas supply outlook and may benefit other LNG developers.

Boosts Nigeria's upstream activity and local content participation.

Limited; primarily relevant to energy investors tracking gas project pipelines.

Counterpoint

The project's modest size may not materially affect TotalEnergies' earnings, limiting price impact.

Key entities

  • TotalEnergies

    French energy major, US‑listed as TTE.

  • AMNI

    Nigerian partner holding 60% of the project.

Related articles

$TTELow

A TotalEnergies project will send Caspian gas to Turkey and Azerbaijan

TotalEnergies has approved the Absheron Full Field Development project in the Caspian Sea, aiming to boost gas production to 6 BCMA and 47,000 barrels per day of condensate by 2029. The project, designed to minimize emissions, will supply gas to Azerbaijan, Turkey, and the domestic market. According to the company, it aligns with their strategy of low-cost, low-emission projects.

$TTEMed

TotalEnergies (TTE) Eyes a Bigger $16 Billion Bet on Iraq: Could this Unlock More Growth?

TotalEnergies (TTE) and Iraq's government are discussing energy projects, potentially increasing investments from $12B to $16B. CEO Patrick Pouyanne aims to boost Iraq's oil production, leveraging existing infrastructure like the $10B Gas Growth Integrated Project (GGIP). Projects could support TTE's 3% production growth target by 2026, but details and geopolitical risks remain unclear.

Med

TotalEnergies falls 10% as NGX Oil and Gas Index retreats from record high

TotalEnergies Marketing Nigeria Plc shares fell 10% on Friday, September 25, 2026, to N518.40, reducing the NGX Oil and Gas Index by 0.13%. The decline contrasts with the company's improved Q2 2026 financial results, which showed a 22% revenue increase and a return to profitability. Seplat Energy Plc gained marginally, extending its year-to-date increase to 175.44%.

$BPMed

Wall Street analyst calls for the week of Sep 21–25, 2026

Wall Street analysts highlighted energy, AI infrastructure, and agriculture as key themes. BP (BP) and Chevron (CVX) were upgraded, while TotalEnergies (TTE) saw mixed views. Marathon Petroleum and Akamai (AKAM) were noted for AI infrastructure. Deere & Company (DE) rose on crop price expectations. Moderna (MRNA) faced polarizing views ahead of trial results.